Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19908155 | 0.94 | GPR119 (0.52) | GPR119USP30TRPV3PRMT5WDR77 | |
| SCHEMBL31602655 | 0.92 | GPR119 (0.50) | GPR119UCHL1DPP4 | |
| SCHEMBL31602843 | 0.89 | GPR119 (0.43) | GPR119USP30PRMT5WDR77DPP4 | |
| SCHEMBL31602551 | 0.87 | GPR119 (0.53) | GPR119DPP4 | |
| SCHEMBL18183742 | 0.87 | GPR119 (0.53) | GPR119DPP4 | |
| SCHEMBL18183590 | 0.85 | GPR119 (0.42) | GPR119USP30TRPV3UCHL1 | |
| SCHEMBL13502910 | 0.83 | GPR119 (0.49) | GPR119USP30TRPV3PRMT5WDR77 | |
| SCHEMBL3611065 | 0.83 | GPR119 (0.49) | GPR119USP30TRPV3PRMT5WDR77 | |
| SCHEMBL3611070 | 0.83 | GPR119 (0.49) | GPR119USP30TRPV3PRMT5WDR77 | |
| SCHEMBL3611067 | 0.83 | GPR119 (0.49) | GPR119USP30TRPV3PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118750-A1 | IMIDAZO ISOINDOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3287461-A1 | IMIDAZO ISOINDOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118750-A1 | IMIDAZO ISOINDOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | IDO1, IDO2, TPH1 | GPR119 170/4885USP30 4380/4885TRPV3 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.